Stock comparison
CorMedix
Royalty Pharma
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
CRMD
CorMedix
Market cap
$626.05M
Sector
Healthcare
RPRX
Royalty Pharma
Market cap
$23.44B
Sector
Healthcare
Overall winner
Royalty Pharma RPRX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | CRMD | RPRX | Winner |
|---|---|---|---|
| Warren Buffett | 63C | 66C | RPRX |
| Benjamin Graham | 38D | 84A | RPRX |
| Philip Fisher | 64C | 65C | RPRX |
| Peter Lynch | 64C | 60C | CRMD |
| Joel Greenblatt | 48D | 40D | CRMD |
| Charlie Munger | 67D | 68D | RPRX |
| Terry Smith | 71B | 58D | CRMD |
Side-by-side metrics
| Metric | CRMD | RPRX |
|---|---|---|
| Market cap | $626.05M | $23.44B |
| P/E (TTM) | 3.3x | 27.6x |
| EV/EBIT | 3.7x | 19.9x |
| ROIC (TTM) | 27.59% | 8.43% |
| Gross margin | 85.83% | 99.95% |
| Net margin | 45.25% | 33.91% |
| Revenue CAGR 5y | 5.36% | 0.96% |
| EPS CAGR 5y | - | 11.83% |
| Debt / Equity | 0.3x | 1.3x |
| Dividend yield | 0.0% | 1.72% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CRMD leads on
- Revenue CAGR 5y5.36%vs 0.96%+100%
- P/E (TTM)3.3xvs 27.6x+88%
- EV/EBIT3.7xvs 19.9x+81%
- Debt / Equity0.3xvs 1.3x+75%
RPRX leads on
- Dividend yield1.72%vs 0.0%+100%
- Market cap$23.44Bvs $626.05M+97%
- Gross margin99.95%vs 85.83%+14%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.